Why the Myqorzo approvals matter for Cytokinetics stock Cytokinetics (CYTK) is in the spotlight after regulators in both the ...

Cytokinetics has entered a new phase as a commercial-stage biotech following past FDA approval of Myqorzo for symptomatic ...

Cytokinetics, Incorporated CYTK has entered a pivotal phase following the FDA approval of its first drug, Myqorzo (aficamten) ...

SOUTH SAN FRANCISCO, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (“Cytokinetics”) (Nasdaq: CYTK) today announced its intention to offer, subject to market conditions and ...

Shares of Cytokinetics pull back over 11% on Tuesday. The move represents a pullback from strength seen on Monday. From tariffs to inflation, macro risks are rising—Matt Maley reveals how he’s trading ...

(Reuters) -Cytokinetics said on Wednesday that its experimental heart disease drug met the main goal of a keenly awaited late-stage study, putting it on track to compete with a rival treatment from ...

Hot Line Presentation of Primary Results from ACACIA-HCM to Elaborate on Positive Topline Results in Patients with Non-Obstructive Hypertrophic ...

Investors with a lot of money to spend have taken a bearish stance on Cytokinetics (NASDAQ:CYTK). And retail traders should know. We noticed this today when the positions showed up on publicly ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...

California-based biotech Cytokinetcs (NASDAQ: CYTK) finished the trading week in style, as its stock price outperformed many other titles by rising nearly 5% on Friday. News of a fresh licensing deal ...

SOUTH SAN FRANCISCO, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company management team will participate in the following ...

SOUTH SAN FRANCISCO, Calif., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (CYTK) today announced that the U.S. Food and Drug Administration (FDA) has approved MYQORZO™ (aficamten), 5 ...